KRAS and colorectal carcinoma: Studies also show that the genome of patients with CRC adapts dynamically to intermittent drug schedules that provide a molecular explanation for the efficacy of anti-EGFR rechallenge therapies.47 Patients with KRAS wild-type mCRC can remain KRAS wild-type post-progression.